It’s a bit vague from the context whether the value of the...

It’s a bit vague from the context whether the value of the market opportunity is from the full sale price for biohorizon. That’s what my assumption would be.

And seeing as they’ve given those two exact numbers:
- greater than “5m” procedures
- greater than “$720m” retail market opportunity
It would indicate BH is selling Striate on market for a minimum of $144/unit (720 divided by 5).

The other option is they’re saying that’s the market opportunity for OCC’s cut, but I think that’s way too optimistic.

So unless I’ve completely oversimplified it, I think we may have our average Striate retail price that BH is selling it for?I say average because US healthcare system means it can probably retail price much higher there compared to other global prices. Price OCC gets for manufacturing per unit still up for debate! But my lowest estimate was $45/unit which at 5m units would be… a fair bit. We’re a while off manufacturing capabilities for that though